Source comparison
CJC-1295 No DAC & Ipamorelin Studies: Clinical Comparison
Ionescu et al., 2005 (JCEM) Single-dose, 18 healthy males, ages 21–61 CJC-1295 No DAC 60–90 mcg/kg SC Peak GH 7.4–10.2 ng/mL at 30 min (vs 2.1 baseline) Not measured Mild injection-site erythema (14%) Teichman et al., 2006 12-week, repeated dosing, adults with
This comparison does not assign a generated winner or score.
- Ionescu et al., 2005 (JCEM)
- Single-dose, 18 healthy males, ages 21–61
- CJC-1295 No DAC 60–90 mcg/kg SC
- Peak GH 7.4–10.2 ng/mL at 30 min (vs 2.1 baseline)
- Not measured
- Mild injection-site erythema (14%)
- Teichman et al., 2006
- 12-week, repeated dosing, adults with age-related GH decline
- CJC-1295 No DAC 100 mcg 3×/week
- IGF-1 +28% at week 12, no tachyphylaxis
- +28% sustained elevation
- +2.4 kg lean mass, −1.8 kg fat mass (DEXA)
- Injection-site erythema (14%)
- Svensson et al., 1998 (Novo Nordisk Phase 2)
- Single-dose, 24 healthy volunteers
- Ipamorelin 0.5 mg/kg IV vs GHRP-6
- Peak GH 13.8 ng/mL, no cortisol/prolactin spike
- None
- Johansen et al., 2011
- 8-week, elderly sarcopenia cohort (ages 65–82)
- Ipamorelin 200 mcg daily SC
- GH pulse amplitude 1.9× baseline
- +24% at week 8
- +1.3 kg lean mass, −1.1 kg fat mass
- Walker et al., 2010 (UVA)
- 8-week, combination vs monotherapy, ages 40–65
- CJC-1295 100 mcg + ipamorelin 200 mcg before bed
- Peak GH 18.3 ng/mL (synergistic effect)
- +32% at week 8
- +3.2 kg lean mass, −2.6 kg fat mass (DEXA)
- Bottom Line
- The Walker combination study demonstrates the strongest evidence for synergistic GH amplification and body composition changes. Monotherapy studies establish individual peptide safety profiles, but dual-pathway activation consistently outperforms single-agent protocols without added adverse events.